NU Skin Enterprises price to sales ratio NUS

Market value divided by revenue over the last twelve months, since 2017.

Today, Oct 23, 2026: 0.2×
9-year median: 0.9×
Against its 9-year history: 2nd; percentile: 0 is its lowest day, 100 its highest
9-year range: 0.2× to 1.9×
Peer median: 2.2×

NU Skin Enterprises' price to sales ratio is 0.2× as of Oct 23, 2026.

That is below its 9-year median of 0.9×, lower than on 98% of days in the last 9 years.

Over that time it ranged from 0.2× in Apr 2025 to 1.9× in Jun 2018.

The median for 10 healthcare stocks of a similar size is 2.2×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.2×	0.2×	0.4×
2025	0.3×	0.2×	0.4×
2024	0.2×	0.2×	0.5×
2023	0.5×	0.4×	1.0×
2022	0.9×	0.7×	1.0×
2021	0.9×	0.7×	1.3×
2020	1.2×	0.4×	1.3×
2019	0.9×	0.8×	1.4×
2018	1.3×	1.2×	1.9×
2017	1.7×	1.3×	1.7×

Against its peers

Companies in Healthcare nearest NU Skin Enterprises' size, closest first, today.

Company	Price to sales ratio
NUSNU Skin Enterprises	0.2×
UTMDUtah Medical Products	6.5×
ELMDElectromed	3.0×
NATRNatures Sunshine Products	0.4×
PLXProtalix BioTherapeutics	2.5×
PDEXPro DEX	2.6×
INFUInfuSystem	1.9×
VMDViemed Healthcare	1.2×
EMBCEmbecta	0.4×
ARVNArvinas	1.5×
NRCNRC Health	3.5×
Peer median	2.2×

Where NU Skin Enterprises ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on NU Skin Enterprises

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.